Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

(2022) Alexander C. J. van Akkooi et al.   ANNALS OF SURGICAL ONCOLOGY

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

(2022) Irene L. M. Reijers et al.   JAMA Surgery

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

(2021) Judith M. Versluis et al.   EUROPEAN JOURNAL OF CANCER

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

(2021) R.V. Rawson et al.   ANNALS OF ONCOLOGY

Application of ultrasound-guided placement of markers for locating axillary lymph nodes of breast cancer

(2021) Xiaohui Ji et al.   Gland Surgery

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

(2020) Reinhard Dummer et al.   LANCET ONCOLOGY

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.

(2020) Alexander M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

(2020) C. Robert et al.   ANNALS OF ONCOLOGY

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

(2020) Paolo A Ascierto et al.   LANCET ONCOLOGY

Long-term safety and efficacy of breast biopsy markers in clinical practice

(2020) Sharon Smith et al.   Expert Review of Medical Devices

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

(2019) B. Schermers et al.   BRITISH JOURNAL OF SURGERY

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

(2019) Y J L Jansen et al.   ANNALS OF ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In‐transit Disease

(2019) J. Weber et al.   BRITISH JOURNAL OF DERMATOLOGY

Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research

(2019) Johannes M. Giesinger et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema

(2017) Caroline A. Gjorup et al.   EUROPEAN JOURNAL OF CANCER

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Pointwise confidence intervals for a survival distribution with small samples or heavy censoring

(2013) Michael P. Fay et al.   BIOSTATISTICS

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma

(2009) Mattijs de Vries et al.   ANNALS OF SURGICAL ONCOLOGY

Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection

(2009) Lutz Kretschmer et al.   MELANOMA RESEARCH